Skip to content
Open access

Identification of Natural Flavonoids Targeting PLK-1 as Potential Anti-Metastatic Agents: A Computational Approach

Jul 2026 · International Journal of Molecular Sciences · Vol 27 · 0 citations · 99 references
Medicine

TL;DR

This study combines ligand- and structure-based in silico strategies to predict the inhibitory activity of natural flavonoids on the Polo-Like Kinase-1 (PLK-1) enzyme as candidate anticancer agents, offering a robust methodological framework for proposing candidates with a higher probability of success in subsequent stages of experimental validation, reducing time and costs in the early stages of drug development.

Abstract

This study combines ligand- and structure-based in silico strategies to predict the inhibitory activity of natural flavonoids on the Polo-Like Kinase-1 (PLK-1) enzyme as candidate anticancer agents. This enzyme participates in mitosis and is overexpressed in cancer cells. Furthermore, it has been shown to have important implications for tumor metastasis, and its inhibitors are attractive starting points for drug development. First, classification models are developed using linear discriminant analysis and a multilayer perceptron neural network. Models with accuracy greater than 80%, validated using standard statistical performance metrics and applicability domain, are used for virtual screening identifying four compounds as potential antitumor drugs. Subsequently, the identified compounds are evaluated using a molecular docking methodology to verify their binding mode and interactions with the catalytic domain of PLK-1. Finally, the integration of molecular dynamics simulations, at 300 ns, with Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) thermodynamic calculations demonstrates that the hydroxylation pattern of ring B in the flavonol scaffold is the fundamental chemical-structural determinant of electrostatic interactions and the architecture of water-mediated networks. Among the evaluated flavonoids, myricetin showed the most favorable overall computational profile, including the highest virtual-screening score and the most favorable mean MM/GBSA estimate, supporting its prioritization for experimental evaluation as a potential PLK-1 inhibitor. The integration of these approaches offers a robust methodological framework for proposing candidates with a higher probability of success, in subsequent stages of experimental validation, reducing time and costs in the early stages of drug development.

Read PDF

Similar papers

Open access Jul 2026

Exploring the Breast Cancer Inhibitor from Flavone Subclass: In Silico and In Vitro Assays

It is suggested that amentoflavone has potential as a natural lead compound for further optimization and development of ERα-targeted therapies in ER-positive breast cancer.

D. S. F. Ramadhan, Nurisyah Nurisyah, Asyhari Asyikin et al. · 0 citations
Aug 2026

Identification of the Potential of Plant-Derived Agents to Act as KRAS G12D Inhibitors Through Molecular Docking, Molecular Dynamics Simulations, and MMGBSA.

INTRODUCTION/OBJECTIVE The KRAS G12D mutation is a significant oncogenic factor that promotes cell proliferation and tumor development, particularly in pancreatic cancer. Inhibiting the mutated form of the KRAS protein is a critical strategy in cancer treatment. While molecules like MRTX1133 show promise, the limited e...

Ebru Okutan, Serra Özışık, V. Atalay · 0 citations
Open access Jul 2026

QSAR of Novel Chrysin Benzimidazole Derivatives for Potential Anti-Cancer Agents

Light is shed on the structural prerequisites for anticancer action, which may aid in the rational development of more effective benzimidazole-based medicinal medicines, and emphasizing the significance of descriptors such as molar refractivity, partition coefficient, and related factors.

Arun Kumar Rai, Keerti Sahu, Megha Chouhan et al. · 0 citations
Aug 2026

In silico identification and biological evaluation of newly synthetic hinokiflavone derivatives as multi-kinase inhibitors with preferential Aurora A activity for ovarian cancer therapy.

Aurora A kinase overexpression has been implicated in ovarian cancer progression, highlighting its potential as a therapeutic target. In this study, we performed structure-based virtual screening of our proprietary natural product database, identifying hinokiflavone (HNK) as a novel Aurora A inhibitor. Kinase profiling...

Ke Wang, Guan-Yu Chen, Pei-Yi Chu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.